PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer

被引：0
|
作者：
Kim, Hyo Song
Zhang, Xianglan
Park, Kyu Hyun
Park, Ji Soo
Kim, Ki Hyang
Chung, Hyun Cheol
Rha, Sun Young
机构：
[1] Yonsei Univ Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ Coll Dent, Oral Canc Res Inst, Seoul, South Korea
[3] Yonsei Univ Coll Med, Canc Metastasis Res Ctr, Seoul, South Korea
[4] Yonsei Univ Coll Med, Div Med Oncol, Dept Internal Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Inje Univ Coll Med, Busan Paik Hosp, Div Hematol Oncol, Dept Internal Med, Pusan, South Korea
[6] Yonsei Univ Heath Syst, Yonsei Canc Ctr, Seoul, South Korea
[7] Yonsei Univ Coll Med, Yonsei Canc Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4089
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer
    Kubota, Tetsushi
    Kuroda, Shinji
    Kanaya, Nobuhiko
    Morihiro, Toshiaki
    Aoyama, Katsuyuki
    Kakiuchi, Yoshihiko
    Kikuchi, Satoru
    Nishizaki, Masahiko
    Kagawa, Shunsuke
    Tazawa, Hiroshi
    Fujiwara, Toshiyoshi
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2018, 14 (06) : 1919 - 1929
  • [32] Resistance to Targeted Inhibitors of the PI3K/AKT/mTOR Pathway in Advanced Oestrogen-Receptor-Positive Breast Cancer
    Browne, Iseult M.
    Okines, Alicia F. C.
    CANCERS, 2024, 16 (12)
  • [33] HER3 mediates acquired resistance to HER2-targeted therapy in esophageal adenocarcinoma
    Ebbing, Eva A.
    Medema, Jan Paul
    Meijer, Sybren L.
    Krishnadath, Kausilia K.
    Henegouwen, Mark I. van Berge
    Bijlsma, Maarten F.
    van Laarhoven, Hanneke W. M.
    CANCER RESEARCH, 2015, 75
  • [34] Targeting the PI3K signaling pathway in cancer therapy
    Bartholomeusz, Chandra
    Gonzalez-Angulo, Ana Maria
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 121 - 130
  • [35] Targeted molecular therapy of the PI3K pathway - Therapeutic significance of PI3K subunit targeting in colorectal carcinoma
    Rychahou, Piotr G.
    Jackson, Lindsey N.
    Silva, Scott R.
    Rajaraman, Srinivasan
    Evers, B. Mai
    ANNALS OF SURGERY, 2006, 243 (06) : 833 - 844
  • [36] MicroRNAs and the PTEN/PI3K/Akt pathway in gastric cancer
    Hu, Mingli
    Zhu, Shixuan
    Xiong, Shengwei
    Xue, Xingxing
    Zhou, Xiaodong
    ONCOLOGY REPORTS, 2019, 41 (03) : 1439 - 1454
  • [37] Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Nahta, Rita
    Yu, Dihua
    Hung, Mien-Chie
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 269 - 280
  • [38] Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta
    Dihua Yu
    Mien-Chie Hung
    Gabriel N Hortobagyi
    Francisco J Esteva
    Nature Clinical Practice Oncology, 2006, 3 : 269 - 280
  • [39] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [40] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    MEDICINE, 2024, 103 (24) : e38508
12345